These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 20351977)

  • 1. Platelet-rich plasma: support for its use in wound healing.
    Lacci KM; Dardik A
    Yale J Biol Med; 2010 Mar; 83(1):1-9. PubMed ID: 20351977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
    Miller MS
    J Foot Ankle Surg; 1999; 38(3):227-31. PubMed ID: 10384364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
    Nagai MK; Embil JM
    Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of recombinant growth factors in wound healing.
    Robson MC; Mustoe TA; Hunt TK
    Am J Surg; 1998 Aug; 176(2A Suppl):80S-82S. PubMed ID: 9777977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
    Embil JM; Papp K; Sibbald G; Tousignant J; Smiell JM; Wong B; Lau CY
    Wound Repair Regen; 2000; 8(3):162-8. PubMed ID: 10886806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ; Smiell JM; Su Y
    Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical promise of becaplermin (rhPDGF-BB) in wound healing.
    LeGrand EK
    Am J Surg; 1998 Aug; 176(2A Suppl):48S-54S. PubMed ID: 9777972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Regranex gel for diabetic foot ulcers.
    Piascik P
    J Am Pharm Assoc (Wash); 1998; 38(5):628-30. PubMed ID: 9782698
    [No Abstract]   [Full Text] [Related]  

  • 9. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee.
    Ladin D
    Plast Reconstr Surg; 2000 Mar; 105(3):1230-1. PubMed ID: 10724287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers.
    Papanas N; Maltezos E
    Clin Interv Aging; 2008; 3(2):233-40. PubMed ID: 18686746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence on the use of platelet-rich plasma for diabetic ulcer: a systematic review.
    Villela DL; Santos VL
    Growth Factors; 2010 Apr; 28(2):111-6. PubMed ID: 20001406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous platelet-rich plasma for treating chronic wounds.
    Martinez-Zapata MJ; Martí-Carvajal AJ; Solà I; Expósito JA; Bolíbar I; Rodríguez L; Garcia J
    Cochrane Database Syst Rev; 2012 Oct; 10():CD006899. PubMed ID: 23076929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
    Wieman TJ
    Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured with genetic technology].
    Fruhstorfer B
    Internist (Berl); 2000 Jan; 41(1):A38. PubMed ID: 10712088
    [No Abstract]   [Full Text] [Related]  

  • 15. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer.
    Lantis JC; Boone D; Gendics C; Todd G
    Adv Skin Wound Care; 2009 Apr; 22(4):167-71. PubMed ID: 19325276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healing and preventing the diabetic foot wound: where technology, economics and common sense converge.
    Armstrong DG
    Indian J Med Sci; 2007 Jun; 61(6):324-5. PubMed ID: 17558094
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel.
    Castronuovo JJ; Ghobrial I; Giusti AM; Rudolph S; Smiell JM
    Am J Surg; 1998 Aug; 176(2A Suppl):61S-67S. PubMed ID: 9777974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
    Smiell JM; Wieman TJ; Steed DL; Perry BH; Sampson AR; Schwab BH
    Wound Repair Regen; 1999; 7(5):335-46. PubMed ID: 10564562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced skin wound healing by a sustained release of growth factors contained in platelet-rich plasma.
    Yang HS; Shin J; Bhang SH; Shin JY; Park J; Im GI; Kim CS; Kim BS
    Exp Mol Med; 2011 Nov; 43(11):622-9. PubMed ID: 21847007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatments in ulcer healing and wound infection.
    Edmonds M; Bates M; Doxford M; Gough A; Foster A
    Diabetes Metab Res Rev; 2000; 16 Suppl 1():S51-4. PubMed ID: 11054889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.